raloxifene hydrochloride has been researched along with carbitol in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Beg, S; Jain, A; Jain, S; Kaur, R; Kushwah, V; Singh, B | 1 |
| Kohli, K; Mangla, B; Neupane, YR; Singh, A; Sonali, LJ; Soni, NK | 1 |
2 other study(ies) available for raloxifene hydrochloride and carbitol
| Article | Year |
|---|---|
Novel cationic supersaturable nanomicellar systems of raloxifene hydrochloride with enhanced biopharmaceutical attributes.
Topics: Animals; Biological Transport; Caco-2 Cells; Cell Survival; Chemistry, Pharmaceutical; Drug Delivery Systems; Drug Liberation; Emulsions; Estrogen Antagonists; Ethylene Glycols; Humans; Hypromellose Derivatives; Intestinal Mucosa; MCF-7 Cells; Micelles; Models, Biological; Nanoparticles; Polyethylene Glycols; Polymers; Propylene Glycols; Raloxifene Hydrochloride; Rats, Sprague-Dawley | 2018 |
Nanostructured lipid carrier potentiated oral delivery of raloxifene for breast cancer treatment.
Topics: Administration, Oral; Animals; Antineoplastic Agents; Breast Neoplasms; Drug Carriers; Ethylene Glycols; Fatty Acids; Female; Humans; MCF-7 Cells; Nanostructures; Raloxifene Hydrochloride; Rats, Wistar; Selective Estrogen Receptor Modulators | 2020 |